MPNs

Latest News

Evolving Roles of JAK Inhibitors in Cytopenic Myelofibrosis
Evolving Roles of JAK Inhibitors in Cytopenic Myelofibrosis

September 22nd 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, discussed the development of Janus kinase inhibitors and how newer therapies meet needs of patients with cytopenic myelofibrosis.

FDA Fast Tracks MWTX-003 for Polycythemia Vera Treatment
FDA Fast Tracks MWTX-003 for Polycythemia Vera Treatment

September 21st 2023

Behind the FDA Approval: Momelotinib for Myelofibrosis and Anemia
Behind the FDA Approval: Momelotinib for Myelofibrosis and Anemia

September 20th 2023

FDA Approves Momelotinib for the Treatment of Myelofibrosis and Anemia
FDA Approves Momelotinib for the Treatment of Myelofibrosis and Anemia

September 15th 2023

Ropeginterferon Alfa-2b-Njft Challenges Standard Chemotherapy in Patients With ET
Ropeginterferon Alfa-2b-Njft Challenges Standard Chemotherapy in Patients With ET

September 12th 2023

More News